Nautilus Biotechnology (NASDAQ:NAUT) Posts Earnings Results, Beats Expectations By $0.03 EPS

Nautilus Biotechnology (NASDAQ:NAUT) posted its quarterly earnings results on Tuesday. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03, FiscalAI reports. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.10 million.

Here are the key takeaways from Nautilus Biotechnology’s conference call:

• Nautilus is reallocating most application-specific R&D toward proteoform assays, citing strong customer demand and confidence that its platform offers unique, single-molecule resolution. The company expects roughly 20 proteoform assays by mid-2028, with AKT1 entering early access in late 2026 and multiple assays targeting general availability in 2027.
• Broadscale development has fallen behind schedule: recent testing did not sufficiently improve probe performance to support 2027 general availability at the targeted specifications. Management provided no replacement timeline and plans to reduce the Broadscale team by roughly half while maintaining a focused technical effort.
• The company reported lower-than-planned expenses and now expects full-year operating expense growth of less than 10%, while its $129.2 million in cash, cash equivalents, and investments is projected to fund operations into the first quarter of 2028.
• Commercial revenue remains very limited: second-quarter revenue was only $0.2 million, primarily from a Michael J. Fox Foundation grant, and full-year revenue guidance remains approximately $0.5 million. Management also anticipates raising debt and/or equity between now and mid-2027 to fund proteoform expansion and market development.
• Nautilus remains on track to place a beta instrument in 2026, open Voyager pre-orders in early 2027, and begin shipments in mid-2027 at a targeted instrument price of roughly $1 million, with consumables expected to cost several thousand dollars per sample. Management views oncology, particularly AKT1 and future biofluid applications, as a substantially larger near-term opportunity than its current brain-tissue-focused neurodegeneration offering.

Nautilus Biotechnology Stock Performance

NASDAQ NAUT traded down $0.01 on Thursday, reaching $1.02. 555,921 shares of the stock traded hands, compared to its average volume of 480,796. Nautilus Biotechnology has a 12 month low of $0.62 and a 12 month high of $4.31. The company has a market cap of $130.26 million, a price-to-earnings ratio of -2.28 and a beta of 0.80. The company has a fifty day moving average price of $2.08 and a 200-day moving average price of $2.43.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research note on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $4.00.

Insider Activity

In other news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $2.35, for a total transaction of $11,750,000.00. Following the transaction, the insider owned 971,885 shares of the company’s stock, valued at approximately $2,283,929.75. This represents a 83.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 41.10% of the company’s stock.

Institutional Trading of Nautilus Biotechnology

Hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC increased its position in Nautilus Biotechnology by 5.4% during the 4th quarter. Millennium Management LLC now owns 1,019,996 shares of the company’s stock valued at $1,989,000 after purchasing an additional 52,448 shares during the period. Geode Capital Management LLC lifted its position in shares of Nautilus Biotechnology by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 560,909 shares of the company’s stock worth $1,094,000 after purchasing an additional 7,307 shares during the period. Corient Private Wealth LLC lifted its position in shares of Nautilus Biotechnology by 860.0% in the 2nd quarter. Corient Private Wealth LLC now owns 435,350 shares of the company’s stock worth $316,000 after purchasing an additional 390,000 shares during the period. Jacobs Levy Equity Management Inc. boosted its stake in shares of Nautilus Biotechnology by 18.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 301,012 shares of the company’s stock valued at $254,000 after purchasing an additional 46,153 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Nautilus Biotechnology by 152.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 297,437 shares of the company’s stock valued at $580,000 after purchasing an additional 179,721 shares in the last quarter. 50.71% of the stock is owned by hedge funds and other institutional investors.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.